Cystic Fibrosis Therapeutics Market Outlook - 2026
The global cystic fibrosis therapeutics market size was valued at $4,615.4 million in 2018 and is expected to reach $9,277.3 million by 2026, registering a CAGR of 9.2% from 2019 to 2026.
Cystic fibrosis is a hereditary disorder, which majorly affects lungs and other body parts such as pancreas, liver, and kidney. It is caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This gene is located in chromosome number 7, and is responsible for the regulation of sweat, mucus, and body secretions. However, mutation of this gene leads to absence of CFTR activity, which in turn results in loss of chloride and alters the protein structure. Patients experience difficulty in breathing, mucus formation, fatty stool, and difficulty in the passageway of the pancreas, bile duct, intestine, & salivary gland. Cystic fibrosis is diagnosed by the use of sweat test and genetic testing. Physical therapy is used for the treatment of cystic fibrosis that helps in the reduction of mucus formation and fights against infections of an organ. In addition, treatment of cystic fibrosis includes the use of drugs such as Pulmozyme, Kalydeco, and others. These drugs can be administered to the patient by different routes such as oral and by inhalation.
The global cystic fibrosis therapeutics market is expected to witness significant growth during the forecast period majorly due to availability of personalized drug therapy & molecular prosthetics for the treatment of cystic fibrosis. Furthermore, rise in prevalence of cystic fibrosis and surge in awareness about cystic fibrosis across the globe boost the cystic fibrosis market trend. For instance, according to the Cystic Fibrosis Foundation Patient Registry, in the U.S. more than 30,000 people are living with cystic fibrosis and more than 70,000 worldwide. In addition, approximately 1,000 new cases of CF are diagnosed each year and more than 75 % of people with CF are diagnosed by age 2. Moreover, increase in R&D investments made by government in the healthcare sector drives the cystic fibrosis therapeutics market growth. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Developing nations such as countries of Asia-Pacific region are not so aware reading the cystic fibrosis diagnosis of the newborns. Further, in various countries, new born are not tested for CF during birth and national registries are lacking in data, thereby hampering the cystic fibrosis market growth. On the contrary, the introduction of various new drugs with better productivity and development of the healthcare R&D facilities are expected to create lucrative opportunities in the cystic fibrosis therapeutics market. Moreover, development of the healthcare industry and increase in R&D activities undertaken by key players are expected to boost the market growth during the forecast period. Furthermore, rise in prevalence of cystic fibrosis has generated need for newer and advanced therapeutics for its treatment. Hence, this has led to increase in number of pipeline drugs in the market, which is expected to provide remunerative opportunities for market expansion during the forecast period.
Global Cystic Fibrosis Therapeutics Market Segmentation
The global cystic fibrosis therapeutic market is segmented on the basis of drug class, route of administration, top selling drug, and region. On the basis of drug class, the market is divided into pancreatic enzyme supplements, mucolytic, bronchodilators, and CFTR modulators. Depending on route of administration, it is classified into oral and inhaled. By top selling drug, the market is segregated into pulmozyme, Creon, kalydeco, cayston, azithromycin, tobramycin and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Drug Class segment review
Based on cystic fibrosis therapeutics market analysis, the CFTR modulators segment dominated the market in 2018 and is anticipated to continue its dominance during the forecast period. This is attributed to increased usage of these drugs for the treatment of cystic fibrosis. This segment is also estimated to grow at the fastest rate during the forecast period. Further, the introduction of CFTR drugs, Kalydeco, Orkambi and Symdeko is one such innovation. These drugs are now widely being used for the treatment of cystic fibrosis and many other CFTR drugs are under clinical trials. The main target of these drugs is to increase the life expectancy of the patients. Moreover, advances in the diagnosis and therapeutics has significantly increased the survival of patients.
By Drug Class
CFTR modulators segment is projected as one of the most lucrative segments.
Route of Administration segment review
By route of administration, the oral segment accounted for the majority of the cystic fibrosis therapeutics market share in 2018, owing to the increased formulation of drugs in oral form; for example, development of CFTR drugs. Further, there are currently three CFTR modulator drugs approved by the U.S. FDA, all of which are oral tablets. These include ivacaftor (kalydeco), orkambi, and symdeko. The market for these oral drugs is anticipated to grow at a fast pace owing to ongoing clinical trials and research & development toward the development of oral CFTR drugs.
By Route Of Administration
Oral route of administration is projected as one of the most lucrative segments.
Europe constitutes the highest market share in the global cystic fibrosis therapeutics market in 2018, followed by North America owing to the increase in incidence of cystic fibrosis. Moreover, increase in governmental support for innovation and rise in funding of projects for R&D of various cystic fibrosis drugs further fuel the market growth in this region. UK is the highest revenue contributor due to increase in prevalence of cystic fibrosis in this region. Moreover, surge in national newborn screening program in the UK propels the market growth. In addition, many companies are involved in developing drugs for individuals who do not get benefitted with CFTR drugs. However, North America is projected to grow at the highest CAGR during the forecast period.
Key players operating in cystic fibrosis therapeutic markets are Genentech, Inc., Novartis AG, Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, AbbVie Inc., GlaxoSmithKline Plc., Johnson & Johnson, Allergan plc, Pharmaxis Ltd., and Mylan N.V.
By Region
North America region would exhibit the highest CAGR of 9.9% during 2019-2026.
Key Benefits for Cystic Fibrosis Therapeutics Market :
- The cystic fibrosis therapeutics market share is based on a comprehensive analysis of key developments in the cystic fibrosis industry.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global cystic fibrosis therapeutics market.
- The cystic fibrosis therapeutics market trends are studied from 2018 to 2026.
- Information about key drivers, restrains, and opportunities and their impact analysis on the cystic fibrosis therapeutics market size is provided.
- Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry.
- The quantitative analysis of the global cystic fibrosis therapeutics market forecast from 2019 to 2026 is provided to determine the market potential.
Cystic Fibrosis (CF) Therapeutics Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Route Of Administration |
|
 By Region |
|
 Key Market Players | AbbVie Inc., Gilead Sciences, Inc., Allergan plc, Vertex Pharmaceuticals Incorporated, Mylan N.V, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Pharmaxis Ltd, GlaxoSmithKline Plc., Novartis AG |
Analyst Review
According to CXOs, cystic fibrosis is a genetic disease that primarily affects the lungs and digestive system, but it can result in lethal disorders such as liver disease and diabetes. Symptoms of cystic fibrosis includes salty-tasting skin, persistent coughing, frequent lung infections including pneumonia or bronchitis, wheezing or shortness of breath, poor growth or weight gain in spite of a good appetite, frequent greasy, bulky stools or difficulty with bowel movements, and infertility. However, cystic fibrosis needs daily care, patients with the condition often have a better quality of life than people with cystic fibrosis had in previous decades. Improvements in treatments against cystic fibrosis has led people to live an increased lifespan.
The cystic fibrosis therapeutics market is expected to witness a substantial growth owing to the surge in incidence of cystic fibrosis. For instance, the disease affects around 30,000 people in the U.S. with around 1,000 new cases diagnosed each year. Of these new diagnoses, 75% are in children under the age of 2 years. Thereby, the U.S. government has made screening of cystic fibrosis compulsory for new born. There have been remarkable advancements in the field of cystic fibrosis treatment and the key market players are focusing toward the development of personalized drug therapy that is anticipated to propel the market growth in near future.
Loading Table Of Content...
